Atom Investors’s Neumora Therapeutics NMRA Stock Holding History

Atom Investors’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,755	Closed	-$46.3K	–	956
2026 Q1	$46.3K	Buy	+23,755	New	+$61.6K	﹤0.01%	636

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atom Investors's NMRA Position: Q2 2026 in Review

Atom Investors sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 23,755 shares — an estimated $46.3K sold.

Atom Investors first reported a position in NMRA in Q1 2026 and held it in 1 quarter. The position peaked at $46.3K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Atom Investors reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
Atom Investors sold 23,755 Neumora Therapeutics shares in Q2 2026, an estimated $46.3K.
Atom Investors first reported a position in Neumora Therapeutics in Q1 2026 and held it in 1 quarter.
Atom Investors's Neumora Therapeutics position peaked at $46.3K in Q1 2026.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.